Sanofi

SNYApproved

Sanofi is one of the world's largest pharmaceutical companies, leveraging artificial intelligence and deep immunology expertise to develop breakthrough treatments and vaccines. With a comprehensive pipeline spanning multiple therapeutic areas and a strong commercial portfolio of established medicines, the company is committed to improving global health outcomes. Their recent focus on AI-powered drug discovery and development positions them at the forefront of pharmaceutical innovation.

Market Cap

$107.3B

Employees

100,000+

Focus

BiologicsSmall MoleculesVaccines

SNY · Stock Price

USD 44.606.93 (-13.45%)

Historical price data

AI Company Overview

Technology Platform

AI-powered drug discovery and development platform with deep expertise in immunology and vaccine development, leveraging artificial intelligence across the entire R&D value chain.

Pipeline Snapshot

1000

1000 drugs in pipeline, 832 in Phase 3

Drug	Indication	Stage
Teriflunomide 14 MG Oral Tablet [Aubagio] + Placebo Oral Tablet	Multiple Sclerosis	Phase 3
RSVt Vaccine + Placebo	RSV Immunisation	Phase 3
Tolebrutinib + Placebo to match Tolebrutinib	Non-relapsing Secondary Progressive Multiple Sclerosis	Phase 3
Lixisenatide (AVE0010)	Diabetes Mellitus, Type 2	Phase 3
Dermacyd Breeze Pocket BR (Lactic Acid)	Hygiene	Phase 3

FDA Approved Drugs

MERILOGBLAFeb 14, 2025

MERILOG SOLOSTARBLAFeb 14, 2025

FEXINIDAZOLENDAJul 16, 2021

Opportunities

Sanofi has significant growth opportunities through its AI-powered R&D platform, robust Phase 3 pipeline with 28 trials, and expansion into emerging markets.

The company's leadership in immunology and vaccines positions it well for continued innovation and market expansion.

Risk Factors

Key risks include patent cliff exposure on major products, increasing pricing pressures from payers and governments, and regulatory approval uncertainties for pipeline candidates.

Competition from biosimilars and the high costs of R&D also present ongoing challenges.

Competitive Landscape

Sanofi competes with major pharmaceutical companies like Pfizer, Roche, and Novartis, differentiating itself through AI-powered drug development, strong immunology franchise, and comprehensive vaccine portfolio. The company's expertise in rare diseases and established diabetes franchise provide competitive moats in specialized therapeutic areas.

Publications

Patents

Pipeline

1000

FDA Approvals